search

Active clinical trials for "Asthma"

Results 3311-3320 of 3412

Phenotyping Circulating and Lung Resident Eosinophils in Severe Asthma (P-CLESA)

Severe Asthma

Title: Phenotyping circulating and lung resident eosinophils in severe asthma (3 years). Background: Asthma is a long-term condition that affects the airways. When a person with asthma comes into contact with something that irritates their sensitive airways, the lungs respond with contracting the muscles around the airway tubes, an inflammation process and mucus production. The airway will become narrower and inflamed making it hard to breathe and results in symptoms such as wheezing and coughing. The treatment of asthma consists of using inhalers that work to widen the airway to relief these symptoms. Often severe asthmatics have difficulty in controlling their disease, despite good medical care and taking asthma medicines. At the moment there is no cure for asthma. A new medicine called Mepolizumab (anti-Interleukin(IL)-5 therapy) has now shown to improve the symptoms of asthma particularly patients with severe asthma in whom the normal medicines prescribed for asthma are not highly effective in controlling their disease. You have been chosen receive this new medicine as we believe it will improve the control of your disease. The aim for this study is to understand the effect of Mepolizumab on a particular type of cell, called an eosinophil, which in present lungs and blood of all people but is increased in asthma patients. Rationale: The relationship between subsets of circulating and lung resident eosinophils in severe asthma and Mepolizumab (anti-IL-5 therapy) efficacy has not been explored. Objectives: To determine the gene expression and release of inflammatory proteins (mediator profiles) of eosinophils from the circulation and the lung, specifically blood and tissue resident, in patients with severe asthma at baseline and on Mepolizumab therapy. Study 1: Phenotype subsets of circulating eosinophils in patients with severe asthma at one time-point Recruit: 15 biologic naïve SA and 15 SA currently on Mepo therapy. Blood eosinophils will be isolated by negative selection. Single-cell RNA-seq 10xGenomics and bulk-RNA-seq to be used to simultaneously measure gene and cell surface protein expression in the same cell to understand cellular heterogeneity in asthmatic eosinophils and identify novel targets and biomarkers for non-responsiveness Study 2: Phenotype subsets of circulating and lung eosinophils in patients with severe asthma on Mepolizumab therapy over one year. Treat 30 appropriately characterised severe asthmatics (Eos>300/ul) with Mepolizumab Blood eosinophils will be isolated by negative selection. Single-cell RNA-seq 10xGenomics and bulk -RNA -seq to be used to understand cellular heterogeneity in asthmatic eosinophils post Mepo Therapy. Sampling at baseline, 3 and 12 months post Mepo Therapy. Bronchoscopy performed on 30 patients, sampling endobronchial lung biopsy at baseline and 1 yr post Mepo Therapy. Single-cell RNA-seq 10xGenomics on lung resident eosinophils at baseline and 1yr post Mepolizumab therapy. Immunohistochemistry will also be performed to characterise cellular content and structure.

Unknown status19 enrollment criteria

Follow-up of Children With Severe Asthma at Adult Age

Severe Asthma

Most of clinical cohorts focused on the course of asthma over time and on the different phenotypes of asthma have investigated children and adults separately. The passage from childhood to adulthood is scarcely explored. In this context, we decided to explore the course of asthma severity from teenage to adulthood in children with severe asthma. The secondary objectives are to assess the quality of life and socioeconomic status in adulthood. This study will be both retrospective (data collected during childhood) and prospective (data collected during adulthood), multicentric and observational

Unknown status6 enrollment criteria

Residual Exacerbations With Mepolizumab

Asthma

This will be a two-year prospective study to characterize the nature of the remaining asthma exacerbations in patients treated with mepolizumab. Participants will be assessed every six months from pre- until two years of treatment in addition to whenever they experience an exacerbation of asthma during the study period. During these visits, various clinical, physiological and inflammatory outcomes will be assessed.

Unknown status5 enrollment criteria

Terbutaline Concentrations in Blood and Urine

Asthma

The purpose of this study is to assess the blood and urine concentrations of terbutaline and to evaluate the difference between inhaled and oral terbutaline in order to distinguish treatment with terbutaline from doping with terbutaline in a doping control.

Unknown status11 enrollment criteria

Sputum and Plasma Levels of Nociceptin and Substance P in Patients With Asthma, COPD and Chronic...

AsthmaCOPD1 more

The aims of this study are to investigate the association between sputum and plasma levels of nociceptin and substance P with cough severity and airway hyperreactivity in patients with asthma, COPD and chronic cough.

Unknown status1 enrollment criteria

Similarities and Differences of Biological Therapies for Severe Asthma.

Asthma

This is an ambispective multicenter longitudinal observational study to evaluate the efficacy and safety profile of biological therapies in patients diagnosed with severe asthma in real life conditions.

Unknown status5 enrollment criteria

Evaluation of Exercise Capacity and Activity Role Adequacy in Patients With Adult Bronchial Asthma...

AsthmaActivity Role Qualification1 more

The aim of this study was to evaluate exercise capacity and activity role adequacy in patients with adult bronchial asthma.

Unknown status8 enrollment criteria

The Relationship Between Kinesiophobia, Physical Activity Level and Quality of Life in Asthma Patients...

Asthma

Asthma is a heterogeneous disease characterized by chronic airway inflammation characterized by time-varying respiratory symptoms such as wheezing, shortness of breath, chest tightness and cough, with limitation of expiratory airflow. These variations are often triggered by exercise, exposure to allergens or an irritation, weather changes or viral respiratory diseases (Karakış, 2018). Increased respiratory distress decreases the patient's activity, decreases the condition and makes the individual dependent in daily life. In the studies conducted in asthma patients, the cases stated that they perceived their illness as an obstacle against physical activity and thus they were pushed to immobility (Kırtay & Oğuz, 2011). In the literature, no study on the variable of kinesiophobia in asthma was found. The aim of this study was to investigate the relationship between kinesiophobia and physical activity level and quality of life in asthma patients.

Unknown status5 enrollment criteria

Efficacy of Mepolizumab in Polish Patients With Severe Eosinophilic Asthma

Asthma; Eosinophilic

This study is aimed at evaluation of the efficacy of mepolizumab 100 mg SC every 4 weeks in patients with severe eosinophilic asthma who have been treated for at least 12 months in several Polish allergy/asthma centres under the same protocol. Target population to be recruited has been set at 130 subjects from at least 6 asthma centers throughout the country. Data on dempgraphics and asthma status will be collected using questionnaires at 3 time-points: pre-MEPO, after 24 weeks of MEPO and after 1 year of MEPO administration (some of the outcomes will be observed every 4 weeks). Primary endpoints will include: Asthma exacerbations measured at qualification for the treatment (in the period of previous 52 weeks) and at the 24th and 52nd week of the treatment. Oral Corticosteroids use dose (documented at qualification for the treatment and at the 24th and 52nd week of the treatment).

Unknown status11 enrollment criteria

A Study on the Effect of Mepolizumab Therapy on Daily Physical Activity of Patients With Severe...

Severe Eosinophilic Asthma

Daily physical activity in adult patients with asthma remains overlooked. Limited evidence demonstrates reduced levels of daily physical activity in asthma populations but studies examining the potential effect of available therapies are missing. This study aims to investigate the overall levels of daily physical activity in patients with severe eosinophilic asthma and whether anti-interleukin-5 therapy with mepolizumab, on top of existing, maximal, and optimised asthma treatment, may improve patient's daily physical activity.

Unknown status2 enrollment criteria
1...331332333...342

Need Help? Contact our team!


We'll reach out to this number within 24 hrs